Headache
| Clinical Trials
Headache
Clinical Trials
Cardiovascular Safety of Erenumab in Patients with Migraine and Aura
book_2
Source:
AHSAM 2020 - Poster session
Published on August 27, 2020
calendar_today
Published on Medfyle:
August 2020
headphones
3
min
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- This study evaluated the cardiovascular and cerebrovascular safety of erenumab in patients with migraine and aura by post hoc safety analysis of pooled data from four double-blind, placebo-controlled erenumab studies and their open-label extensions
- Overall safety profiles were similar across treatment groups during the double-blind treatment phase regardless of aura history
- Cardiovascular, cerebrovascular, and hypertension adverse event rates through the open-label treatment phase were low with no differences between aura subgroups
Presenting Author
Read more
arrow_downward
Hide
arrow_upward
Jeffrey J. Olearczyk, PhD
Senior Medical Science Liaison
Amgen
Thousand Oaks, California
Jeffrey Olearczyk is a Senior Medical Science Liaison at Amgen and supports the neurosience franchise. He received a PhD in Pharmacology and Physiology from Saint Louis University School of Medicine and completed his fellowship at The Medical College of Georgia. Prior to Amgen Jeff was a research scientist in academia and pharma in positions in early drug development and business development.
Author disclosures
Read more
arrow_downward
Hide
arrow_upward
Jeffrey J. Olearczyk, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
